Boehringer Ingelheim completed the acquisition of Nerio Therapeutics for $1.3bn.

Boehringer Ingelheim, an animal health business, completed the acquisition of Nerio Therapeutics, a drug discovery and development company for $1.3bn. “Securing the rights to Nerio Therapeutics' novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities. This brings us a major step closer to our vision of transforming the lives of people living with cancer,” Paola Casarosa, Boehringer Ingelheim Member of the Board of Managing Directors.